Accutar Biotech
AC699 (also called AC0699 on the website) is an oral ERα chimeric degrader. Phase 1 human results and FDA Fast Track were reported in 2024.
Corporate information
- Company entity
- Accutar Biotechnology Inc.／冰洲石生物
- Headquarters / principal office
- Brooklyn, New YorkSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2015 ↗
- Ownership / capital status
- PrivateNew private financing (reported in 2021; round not specified) ↗
- Official corporate reference
- https://www.accutarbio.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2021-04-07 · New financing round (round not specified) · Tens of millions of US dollars (exact amount not disclosed) ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
AC699 (also called AC0699 on the website) is an oral ERα chimeric degrader. Phase 1 human results and FDA Fast Track were reported in 2024.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.